{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-036397","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.119052+00:00","generated_at":"2026-06-09T00:38:08.296721+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vir Biotechnology Q3 net loss $163.4M; revenue down 99% YoY on sotrovimab sales decline","bullets":["Net loss of $163.4M ($1.22/share) vs net income of $175.3M ($1.32/share) in Q3 2022.","Total revenue $2.6M, down 99.3% from $374.6M a year ago due to lower sotrovimab sales.","Cash, equivalents and investments $1.7B; $67M paid to GSK for excess sotrovimab supply.","Secured ~$50M in new BARDA funding to advance next-gen COVID-19 mAb VIR-7229 through Phase 1.","Appointed Jennifer Towne, Ph.D., as EVP and Chief Scientific Officer, effective Nov 6, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-036397","json":"https://secwatch.observer/filing/0001628280-23-036397.json","markdown":"https://secwatch.observer/filing/0001628280-23-036397.md","text":"https://secwatch.observer/filing/0001628280-23-036397.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000162828023036397/0001628280-23-036397-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000162828023036397/vir-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:38:08.296721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a7608ba123c9a9a9071af5158a1bc976208f0a4b","claim":"Vir Biotechnology, Inc. reported third quarter ended September 30, 2023 results: revenue $2.6 million.","evidence_excerpt":"Total revenues for the quarter ended September 30, 2023, were $2.6 million compared to $374.6 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828023036397/0001628280-23-036397-index.htm","confidence":0.924,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$2.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}